Loading clinical trials...
Loading clinical trials...
A Phase 1 First-in-human Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of KPL-404 in Healthy Subjects
Conditions
Interventions
KPL-404
Matching Placebo
Locations
2
United States
PPD Clinic
Austin, Texas, United States
Q-Pharm Pty Ltd
Herston, Queensland, Australia
Start Date
October 22, 2019
Primary Completion Date
January 21, 2021
Completion Date
March 2, 2021
Last Updated
May 4, 2021
NCT00104325
NCT07118891
NCT01399385
NCT07295717
NCT03807401
NCT07271693
Lead Sponsor
Kiniksa Pharmaceuticals, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions